However, in March 2024 the FDA approved resmetirom, an oral thyroid hormone receptor-β (THR-β) agonist, in combination with diet and exercise for the treatment of adults with non-cirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stage F2 to F3 fibrosis) [17]. The gene discussed is THRB; the disease is metabolic dysfunction-associated steatohepatitis.